Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6073501 | 1.00 | MAPT (0.64) | MAPTALDH1A1LMNAHSD11B1SMN1; SMN2 | |
| SCHEMBL29580244 | 0.86 | MAPT (0.62) | MAPTALDH1A1LMNAHSD11B1SMN1; SMN2 | |
| SCHEMBL22471537 | 0.86 | MAPT (0.62) | MAPTALDH1A1LMNAHSD11B1SMN1; SMN2 | |
| SCHEMBL5782039 | 0.86 | MAPT (0.47) | MAPTALDH1A1LMNASMN1; SMN2MEN1 | |
| SCHEMBL18186405 | 0.84 | MAPT (0.60) | MAPTALDH1A1LMNAHSD11B1SMN1; SMN2 | |
| SCHEMBL17958739 | 0.84 | MAPT (0.67) | MAPTALDH1A1LMNAHSD11B1SMN1; SMN2 | |
| SCHEMBL17630358 | 0.84 | MAPT (0.67) | MAPTALDH1A1LMNAHSD11B1SMN1; SMN2 | |
| SCHEMBL5467063 | 0.84 | MAPT (0.67) | MAPTALDH1A1LMNAHSD11B1SMN1; SMN2 | |
| SCHEMBL18436754 | 0.83 | GPR119 (0.56) | MAPTALDH1A1LMNAHSD11B1SMN1; SMN2 | |
| SCHEMBL12004775 | 0.82 | MAPT (0.71) | MAPTALDH1A1LMNASMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7053070-B2 | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2006-05-30 | — | — | US | disclosed |
| EP-1056732-B1 | 4-AMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASES | AGOURON PHARMA (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20030220326-A1 | Compounds, pharmaceutical compositions, and methods for inhibiting cyclin-dependent kinases | CHONG WESLEY K M (US) | 2003-11-27 | — | — | US | disclosed |
| US-6569878-B1 | Such as 4-amino-2-phenylamino-thiazol-5-yl)-(3-nitrophenyl)-methanone for treating cancer | AGOURON PHARMACEUTICALS INC. | 2003-05-27 | — | — | US | disclosed |
| US-20030073668-A1 | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors | BOOTH RICHARD JOHN (US) | 2003-04-17 | — | — | US | disclosed |
| CN-1395578-A | Byrido [2,3-d] pyrimidine-2, 7-diamine kinase inhibitors | WARNER LAMBERT CO (US) | 2003-02-05 | — | — | CN | disclosed |
| EP-1254137-A1 | PYRIDO 2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2002-11-06 | — | — | EP | disclosed |
| EP-1215208-A2 | 4-Aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases | Agouron Pharmaceuticals, Inc. (US) | 2002-06-19 | — | — | EP | disclosed |
| WO-2001055147-A1 | PYRIDO[2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-08-02 | — | — | WO | disclosed |
| EP-1056732-A2 | 4-AMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 2000-12-06 | — | — | EP | disclosed |
| WO-1999021845-A2 | 4-AMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 1999-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220326-A1 | Compounds, pharmaceutical compositions, and methods for inhibiting cyclin-dependent kinases | CDK2, CDK4, CDK1 | MAPT 3466/4885ALDH1A1 1035/4885LMNA 2405/4885 |
| US-20030073668-A1 | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors | CDK9, CDK19, CDK3 | MAPT 4678/4885ALDH1A1 4111/4885LMNA 2415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.